AstraZeneca 미래 성장

Future 기준 확인 4/6

AstraZeneca (는) 각각 연간 18% 및 6.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 18.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 28.7% 로 예상됩니다.

주요 정보

18.0%

수익 성장률

18.8%

EPS 성장률

Pharmaceuticals 수익 성장	76.0%
매출 성장률	6.3%
향후 자기자본 수익률	28.7%
애널리스트 커버리지	Good
마지막 업데이트	18 Nov 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

OM:AZN - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	60,413	11,496	13,913	16,517	22
12/31/2025	57,023	10,175	12,017	14,905	24
12/31/2024	53,142	8,535	7,177	12,169	20
9/30/2024	51,206	6,495	6,867	11,334	N/A
6/30/2024	49,133	6,440	7,045	11,065	N/A
3/31/2024	47,611	6,331	5,887	9,698	N/A
12/31/2023	45,811	5,955	6,858	10,345	N/A
9/30/2023	44,994	5,896	7,270	10,363	N/A
6/30/2023	44,485	6,163	6,854	10,179	N/A
3/31/2023	43,840	4,705	6,357	9,709	N/A
12/31/2022	44,351	3,288	7,684	9,808	N/A
9/30/2022	45,155	2,040	6,538	8,828	N/A
6/30/2022	44,038	-1,253	5,789	7,617	N/A
3/31/2022	41,487	-1,063	5,721	7,261	N/A
12/31/2021	37,417	112	4,350	5,963	N/A
9/30/2021	32,816	1,471	5,184	6,343	N/A
6/30/2021	29,528	3,771	5,421	6,446	N/A
3/31/2021	27,583	3,977	4,899	6,594	N/A
12/31/2020	26,617	3,196	3,144	4,799	N/A
9/30/2020	25,871	2,497	3,273	4,376	N/A
6/30/2020	25,699	2,148	3,057	3,657	N/A
3/31/2020	25,247	1,522	2,789	3,495	N/A
12/31/2019	24,384	1,335	2,585	2,969	N/A
9/30/2019	24,137	2,056	4,230	3,818	N/A
6/30/2019	23,071	2,188	3,543	3,184	N/A
3/31/2019	22,403	2,408	3,621	2,371	N/A
12/31/2018	22,090	2,155	3,585	2,618	N/A
9/30/2018	21,450	2,422	1,202	1,391	N/A
6/30/2018	22,342	2,677	N/A	3,165	N/A
3/31/2018	22,238	2,804	N/A	3,350	N/A
12/31/2017	22,465	3,001	N/A	3,578	N/A
9/30/2017	22,273	3,542	N/A	4,541	N/A
6/30/2017	21,740	3,870	N/A	3,109	N/A
3/31/2017	22,292	3,390	N/A	3,040	N/A
12/31/2016	23,002	3,499	N/A	4,145	N/A
9/30/2016	23,816	2,465	N/A	2,756	N/A
6/30/2016	24,062	2,221	N/A	3,690	N/A
3/31/2016	24,766	2,921	N/A	4,589	N/A
12/31/2015	24,708	2,825	N/A	3,324	N/A
9/30/2015	25,025	1,696	N/A	4,595	N/A
6/30/2015	25,689	1,180	N/A	4,800	N/A
3/31/2015	26,144	1,279	N/A	5,799	N/A
12/31/2014	26,547	1,233	N/A	7,058	N/A
9/30/2014	26,675	1,030	N/A	7,694	N/A
6/30/2014	26,316	2,022	N/A	6,862	N/A
3/31/2014	25,786	2,049	N/A	6,389	N/A
12/31/2013	25,806	2,556	N/A	7,400	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AZN 의 연간 예상 수익 증가율( 18% )이 saving rate( 1.2% 보다 높습니다. ).

수익 vs 시장: AZN 의 연간 수익( 18% ) Swedish 시장( 15.2% 보다 빠르게 성장할 것으로 예상됩니다. 15.2% 연간).

고성장 수익: AZN 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: AZN 의 수익(연간 6.3% ) Swedish 시장( 0.06% 보다 빠르게 성장할 것으로 예상됩니다. 0.06% 연간).

고성장 수익: AZN 의 수익(연간 6.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AZN 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 28.7 %)

AstraZeneca 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Recent updates

Board Member recently bought kr1.4m worth of stock

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Third quarter 2024 earnings released: EPS: US$0.92 (vs US$0.89 in 3Q 2023)

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Independent Chairman recently bought kr3.2m worth of stock

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견